Renal Dysfunction in Heart Failure

Medical Clinics of North America

Volumn 96, Issue 5, 2012, Pages 955-974

  Cole, Robert T ^a   Masoumi, Amirali ^a   Triposkiadis, Filippos ^b   Giamouzis, Gregory ^b   Georgiopoulou, Vasiliki ^a   Kalogeropoulos, Andreas ^a   Butler, Javed ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Cardiorenal syndrome; Chronic kidney disease; Heart failure; Worsening renal function

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FATTY ACID BINDING PROTEIN; FUROSEMIDE; INTERLEUKIN 6; KIDNEY INJURY MOLECULE 1; LOOP DIURETIC AGENT; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR; RANTES; RENIN; SODIUM; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALBUMINURIA; CARDIORENAL SYNDROME; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY PERFUSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SODIUM ABSORPTION; UREA NITROGEN BLOOD LEVEL;

CARDIO-RENAL SYNDROME; DIURETICS; HEART FAILURE; HUMANS; KIDNEY; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84866149241     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.07.005     Document Type: Review

References (146)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med 1991, 325:293-302.
2. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med 1992, 327:685-691.
3. Cleland J.G., Carubelli V., Castiello T., et al. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev 2012, 17:133-149.
4. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35:681-689.
5. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-ADDED trial. Lancet 2003, 362:767-771.
6. Solomon S.D., Wang D., Finn P., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Circulation 2004, 110:2180-2183.
7. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-PRESERVED trial. Lancet 2003, 362:777-781.
8. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
9. de Silva R., Nikitin N.P., Witte K.K., et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006, 27:569-581.
10. Heywood J.T., Fonarow G.C., Costanzo M.R., et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007, 13:422-430.
11. Fonarow G.C., Abraham W.T., Albert N.M., et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007, 167:1493-1502.
12. Cleland J.G., Swedberg K., Follath F., et al. The Euroheart Failure Survey Programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003, 24:442-463.
13. Cowie M.R., Komajda M., Murray-Thomas T., et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the Prospective Outcomes study in Heart Failure (POSH). Eur Heart J 2006, 27:1216-1222.
14. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004, 43:61-67.
15. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8:136-141.
16. Klein L., Massie B.M., Leimberger J.D., et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008, 1:25-33.
17. Krumholz H.M., Chen Y.T., Vaccarino V., et al. Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol 2000, 85:1110-1113.
18. Kociol R.D., Greiner M.A., Hammill B.G., et al. Long-term outcomes of Medicare beneficiaries with worsening renal function during hospitalization for heart failure. Am J Cardiol 2010, 105:1786-1793.
19. Damman K., Navis G., Voors A.A., et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007, 13:599-608.
20. Ronco C., McCullough P.A., Anker S.D., et al. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2010, 165:54-67.
21. Chittineni H., Miyawaki N., Gulipelli S., et al. Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure. Am J Nephrol 2007, 27:55-62.
22. Giamouzis G., Butler J., Triposkiadis F. Renal function in advanced heart failure. Congest Heart Fail 2011, 17:180-188.
23. Giamouzis G., Kalogeropoulos A., Georgiopoulou V., et al. Hospitalization epidemic in patients with heart failure: risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail 2011, 17:54-75.
24. Cruz D.N., Gheorghiade M., Palazzuoli A., et al. Epidemiology and outcome of the cardio-renal syndrome. Heart Fail Rev 2011, 16:531-542.
25. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47:1987-1996.
26. McClellan W.M., Flanders W.D., Langston R.D., et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002, 13:1928-1936.
27. McAlister F.A., Ezekowitz J., Tonelli M., et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004, 109:1004-1009.
28. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
29. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
30. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470.
31. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
32. Froissart M., Rossert J., Jacquot C., et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005, 16:763-773.
33. Smilde T.D., van Veldhuisen D.J., Navis G., et al. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006, 114:1572-1580.
34. Zamora E., Lupon J., Vila J., et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, Chronic Kidney Disease Epidemiology Collaboration, and Cockcroft-Gault formulas. J Am Coll Cardiol 2012, 59:1709-1715.
35. Rich M.W. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol A Biol Sci Med Sci 2001, 56:M88-M96.
36. Croft J.B., Giles W.H., Pollard R.A., et al. Heart failure survival among older adults in the united states: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999, 159:505-510.
37. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009, 119:3070-3077.
38. Lindeman R.D., Tobin J., Shock N.W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985, 33:278-285.
39. Perrone R.D., Madias N.E., Levey A.S. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992, 38:1933-1953.
40. Fehrman-Ekholm I., Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004, 38:73-77.
41. Chrysochou C., Kalra P.A. Current management of atherosclerotic renovascular disease-what have we learned from ASTRAL?. Nephron Clin Pract 2010, 115:c73-c81.
42. van Ampting J.M., Penne E.L., Beek F.J., et al. Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003, 18:1147-1151.
43. Mailloux L.U., Napolitano B., Bellucci A.G., et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney Dis 1994, 24:622-629.
44. Olin J.W., Melia M., Young J.R., et al. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990, 88:46N-51N.
45. Valle R., Aspromonte N., Carbonieri E., et al. Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol 2008, 126:400-406.
46. McClellan W.M., Langston R.D., Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004, 15:1912-1919.
47. Philbin E.F., DiSalvo T.G. Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data. J Am Coll Cardiol 1999, 33:1560-1566.
48. Yamokoski L.M., Hasselblad V., Moser D.K., et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. J Card Fail 2007, 13:8-13.
49. Keenan P.S., Normand S.L., Lin Z., et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 2008, 1:29-37.
50. Nohria A., Hasselblad V., Stebbins A., et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008, 51:1268-1274.
51. Doty J.M., Saggi B.H., Blocher C.R., et al. Effects of increased renal parenchymal pressure on renal function. J Trauma 2000, 48:874-877.
52. Malbrain M.L., Deeren D., De Potter T.J. Intra-abdominal hypertension in the critically ill: it is time to pay attention. Curr Opin Crit Care 2005, 11:156-171.
53. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147:331-338.
54. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
55. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Eur Heart J 1990, 11(Suppl D):44-52.
56. Brecher P. Angiotensin II and cardiac fibrosis. Trends Cardiovasc Med 1996, 6:193-198.
57. Brilla C.G., Pick R., Tan L.B., et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355-1364.
58. McEwan P.E., Gray G.A., Sherry L., et al. Differential effects of angiotensin ii on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998, 98:2765-2773.
59. Lijnen P., Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000, 32:865-879.
60. Lijnen P.J., Petrov V.V., Fagard R.H. Induction of cardiac fibrosis by angiotensin II. Methods Find Exp Clin Pharmacol 2000, 22:709-723.
61. Mezzano S.A., Ruiz-Ortega M., Egido J. Angiotensin II and renal fibrosis. Hypertension 2001, 38:635-638.
62. Ruiz-Ortega M., Gonzalez S., Seron D., et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995, 48:1778-1791.
63. Ruiz-Ortega M., Lorenzo O., Suzuki Y., et al. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001, 10:321-329.
64. Ruiz-Ortega M., Lorenzo O., Ruperez M., et al. Systemic infusion of angiotensin ii into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 2001, 158:1743-1756.
65. Converse R.L., Jacobsen T.N., Toto R.D., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912-1918.
66. Zoccali C., Mallamaci F., Parlongo S., et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002, 105:1354-1359.
67. DiBona G.F. Nervous kidney. Interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension 2000, 36:1083-1088.
68. Salomonsson M., Brannstrom K., Arendshorst W.J. Alpha(1)-adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies. Am J Physiol Renal Physiol 2000, 278:F138-F147.
69. Bakris G.L., Hart P., Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 2006, 70:1905-1913.
70. Osborn J.L., DiBona G.F., Thames M.D. Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther 1981, 216:265-269.
71. Jovanovic D., Jovovic D., Mihailovic-Stanojevic N., et al. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. Clin Nephrol 2005, 63:446-453.
72. Akhter M.W., Aronson D., Bitar F., et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004, 94:957-960.
73. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102:203-210.
74. Hillege H.L., Nitsch D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006, 113:671-678.
75. Ljungman S., Laragh J.H., Cody R.J. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990, 39(Suppl 4):10-21. [discussion: 22-4].
76. Mullens W., Abrahams Z., Skouri H.N., et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function?. J Am Coll Cardiol 2008, 51:300-306.
77. Damman K., van Deursen V.M., Navis G., et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009, 53:582-588.
78. Mullens W., Abrahams Z., Francis G.S., et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009, 53:589-596.
79. Guglin M., Rivero A., Matar F., et al. Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol 2011, 34:113-116.
80. Testani J.M., McCauley B.D., Kimmel S.E., et al. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. Am J Cardiol 2010, 106:1763-1769.
81. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216.
82. Cooper H.A., Dries D.L., Davis C.E., et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100:1311-1315.
83. Ahmed A., Husain A., Love T.E., et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006, 27:1431-1439.
84. Eshaghian S., Horwich T.B., Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006, 97:1759-1764.
85. Domanski M., Norman J., Pitt B., et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003, 42:705-708.
86. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
87. Metra M., Nodari S., Parrinello G., et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008, 10:188-195.
88. Hasselblad V., Gattis Stough W., Shah M.R., et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the escape trial. Eur J Heart Fail 2007, 9:1064-1069.
89. Carubelli V., Metra M., Lombardi C., et al. Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment. Heart Fail Rev 2012, 17:271-282.
90. Testani J.M., Chen J., McCauley B.D., et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010, 122:265-272.
91. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011, 364:797-805.
92. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
93. Bakris G.L., Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med 2000, 160:685-693.
94. Ruiz-Ortega M., Ruperez M., Lorenzo O., et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002, 82:S12-S22.
95. Ljungman S., Kjekshus J., Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] trial). Am J Cardiol 1992, 70:479-487.
96. Oster J.R., Materson B.J. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992, 152:704-710.
97. Valika A.A., Gheorghiade M. Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature. Heart Fail Rev 2012, [Epub ahead of print].
98. Colombo P.C., Ganda A., Lin J., et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012, 17:177-190.
99. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995, 92:1479-1486.
100. Testa M., Yeh M., Lee P., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996, 28:964-971.
101. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:1587-1593.
102. Kozdag G., Ertas G., Kilic T., et al. Elevated level of high-sensitivity C-reactive protein is important in determining prognosis in chronic heart failure. Med Sci Monit 2010, 16:CR156-CR161.
103. Alonso-Martinez J.L., Llorente-Diez B., Echegaray-Agara M., et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002, 4:331-336.
104. Kalra D., Sivasubramanian N., Mann D.L. Angiotensin ii induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 2002, 105:2198-2205.
105. Moriyama T., Fujibayashi M., Fujiwara Y., et al. Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995, 6:95-101.
106. Murray D.R., Prabhu S.D., Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000, 101:2338-2341.
107. Prabhu S.D., Chandrasekar B., Murray D.R., et al. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000, 101:2103-2109.
108. Colombo P.C., Banchs J.E., Celaj S., et al. Endothelial cell activation in patients with decompensated heart failure. Circulation 2005, 111:58-62.
109. Colombo P.C., Rastogi S., Onat D., et al. Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. J Card Fail 2009, 15:457-463.
110. Anker S.D., Egerer K.R., Volk H.D., et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997, 79:1426-1430.
111. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999, 353:1838-1842.
112. Peschel T., Schonauer M., Thiele H., et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2003, 5:609-614.
113. Yhee J.Y., Yu C.H., Kim J.H., et al. Effects of T lymphocytes, interleukin-1, and interleukin-6 on renal fibrosis in canine end-stage renal disease. J Vet Diagn Invest 2008, 20:585-592.
114. Szeto C.C., Kwan B.C., Chow K.M., et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008, 3:431-436.
115. Schwedler S.B., Guderian F., Dammrich J., et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 2003, 18:2300-2307.
116. Radeke H.H., Meier B., Topley N., et al. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 1990, 37:767-775.
117. DiPetrillo K., Coutermarsh B., Gesek F.A. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 2003, 284:F113-F121.
118. Garvin J.L., Ortiz P.A. The role of reactive oxygen species in the regulation of tubular function. Acta Physiol Scand 2003, 179:225-232.
119. Taddei S., Favilla S., Duranti P., et al. Vascular renin-angiotensin system and neurotransmission in hypertensive persons. Hypertension 1991, 18:266-277.
120. Fiksen-Olsen M.J., Strick D.M., Hawley H., et al. Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension 1992, 19:II137-II141.
121. Kastner P.R., Hall J.E., Guyton A.C. Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am J Physiol 1982, 243:F260-F264.
122. Damman K., Voors A.A., Navis G., et al. Current and novel renal biomarkers in heart failure. Heart Fail Rev 2012, 17:241-250.
123. Fonarow G.C., Adams K.F., Abraham W.T., et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293:572-580.
124. Aronson D., Mittleman M.A., Burger A.J. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004, 116:466-473.
125. Comnick M., Ishani A. Renal biomarkers of kidney injury in cardiorenal syndrome. Curr Heart Fail Rep 2011, 8:99-105.
126. Laterza O.F., Price C.P., Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem 2002, 48:699-707.
127. Newman D.J., Thakkar H., Edwards R.G., et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995, 47:312-318.
128. Hoek F.J., Kemperman F.A., Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003, 18:2024-2031.
129. Tidman M., Sjostrom P., Jones I. A comparison of GFR estimating formulae based upon S-cystatin C and S-creatinine and a combination of the two. Nephrol Dial Transplant 2008, 23:154-160.
130. Lassus J., Harjola V.P., Sund R., et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007, 28:1841-1847.
131. Schmidt-Ott K.M., Mori K., Li J.Y., et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007, 18:407-413.
132. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
133. Aghel A., Shrestha K., Mullens W., et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010, 16:49-54.
134. Han W.K., Bailly V., Abichandani R., et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002, 62:237-244.
135. Han W.K., Waikar S.S., Johnson A., et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008, 73:863-869.
136. Damman K., Van Veldhuisen D.J., Navis G., et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010, 96:1297-1302.
137. Westhuyzen J., Endre Z.H., Reece G., et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 2003, 18:543-551.
138. Bazzi C., Petrini C., Rizza V., et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002, 17:1890-1896.
139. Liangos O., Perianayagam M.C., Vaidya V.S., et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007, 18:904-912.
140. Maatman R.G., Van Kuppevelt T.H., Veerkamp J.H. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J 1991, 273(Pt 3):759-766.
141. Ferguson M.A., Vaidya V.S., Waikar S.S., et al. Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int 2010, 77:708-714.
142. Agewall S., Wikstrand J., Ljungman S., et al. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol 1997, 80:164-169.
143. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356-360.
144. van de Wal R.M., Asselbergs F.W., Plokker H.W., et al. High prevalence of microalbuminuria in chronic heart failure patients. J Card Fail 2005, 11:602-606.
145. Jackson C.E., Solomon S.D., Gerstein H.C., et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009, 374:543-550.
146. Masson S., Latini R., Milani V., et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-heart failure trial. Circ Heart Fail 2010, 3:65-72.